A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE)

A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE)

The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma.

Study details include:

1. The study duration will be up to 40 weeks.
2. The treatment duration will be up to 24 weeks.
3. The visit frequency will be once every 4 weeks (Q4W).

Study Overview

• Status: Recruiting
• Conditions: Chronic Rhinosinusitis With Nasal Polyps
• Intervention / Treatment: Combination product: Tezepelumab

Detailed Description

This is a multicentre, open-label, single-arm, phase IIIb study is to describe changes from baseline in (1) participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) and (2) participant-reported sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) following initiation of tezepelumab treatment.

Approximately 60 sites in 10 countries will enrol adult patients with physician determined surgery eligible CRSwNP.

The study is divided into 3 periods as described below:

• Screening Period (from Week -4 until Week 0, up to 4 Weeks)
• Treatment period (Week 0 to Week 24)
• Safety Follow-up Period (Week 24 to Week 36)

• Study Type: Interventional
• Enrollment (Estimated): 180
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: AstraZeneca Clinical Study Information Center; Phone Number: 1-877-240-9479; Email: information.center@astrazeneca.com

Study Locations

• Bulgaria
  • Plovdiv, Bulgaria, 4003
    • Recruiting
    • Research Site
  • Sofia, Bulgaria, 1606
    • Recruiting
    • Research Site
  • Sofia, Bulgaria, 1431
    • Recruiting
    • Research Site
  • Sofia, Bulgaria, 1606
    • Withdrawn
    • Research Site
• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8S 1G5
      • Recruiting
      • Research Site
  • Quebec
    • Québec, Quebec, Canada, G1V 4W2
      • Recruiting
      • Research Site
    • Québec, Quebec, Canada, G1L 3L5
      • Recruiting
      • Research Site
• France
  • Le Kremlin-Bicêtre, France, 94270
    • Recruiting
    • Research Site
  • Lille, France, 59000
    • Withdrawn
    • Research Site
  • Marseille, France, 13005
    • Recruiting
    • Research Site
  • Nantes, France, 44093
    • Recruiting
    • Research Site
  • Pierre-Bénite, France, 69495
    • Recruiting
    • Research Site
  • Poitiers, France, 86000
    • Recruiting
    • Research Site
  • Toulouse, France, 31400
    • Recruiting
    • Research Site
• Germany
  • Düsseldorf, Germany, 40225
    • Withdrawn
    • Research Site
  • Marburg, Germany, 35043
    • Recruiting
    • Research Site
  • Tübingen, Germany, 72076
    • Recruiting
    • Research Site
  • Villingen-Schwenningen, Germany, 78052
    • Recruiting
    • Research Site
  • Wiesbaden, Germany, 65183
    • Recruiting
    • Research Site
• Hungary
  • Budapest, Hungary, 1134
    • Recruiting
    • Research Site
  • Budapest, Hungary, 1085
    • Recruiting
    • Research Site
  • Nyíregyháza, Hungary, 4400
    • Recruiting
    • Research Site
  • Pécs, Hungary, 7621
    • Recruiting
    • Research Site
• Italy
  • Bologna, Italy, 40139
    • Recruiting
    • Research Site
  • Catania, Italy, 95123
    • Recruiting
    • Research Site
  • Florence, Italy, 50139
    • Recruiting
    • Research Site
  • Naples, Italy, 80131
    • Withdrawn
    • Research Site
  • Padua, Italy, 35128
    • Recruiting
    • Research Site
  • Pisa, Italy, 56126
    • Recruiting
    • Research Site
  • Roma, Italy, 00168
    • Recruiting
    • Research Site
  • Rozzano, Italy, 20089
    • Recruiting
    • Research Site
• Poland
  • Bialystok, Poland, 15-879
    • Recruiting
    • Research Site
  • Bydgoszcz, Poland, 85-231
    • Recruiting
    • Research Site
  • Lodz, Poland, 90-302
    • Recruiting
    • Research Site
  • Zawadzkie, Poland, 47-120
    • Recruiting
    • Research Site
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Research Site
  • Barcelona, Spain, 08003
    • Recruiting
    • Research Site
  • Cadiz, Spain, 11011
    • Recruiting
    • Research Site
  • Madrid, Spain, 28041
    • Recruiting
    • Research Site
  • Salamanca, Spain, 37007
    • Recruiting
    • Research Site
  • Santiago de Compostela, Spain, 15706
    • Recruiting
    • Research Site
• United States
  • California
    • Newport Beach, California, United States, 92663
      • Recruiting
      • Research Site
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Recruiting
      • Research Site
  • Massachusetts
    • Chestnut Hill, Massachusetts, United States, 02467
      • Recruiting
      • Research Site
  • Missouri
    • Columbia, Missouri, United States, 65201
      • Recruiting
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants must be 18 years of age or older, at the time of signing the informed consent.
• Participants with physician-diagnosed CRSwNP for at least 12 months prior to Visit 1 who have all of the following:
• Severity consistent with the need for surgery as defined by total NPS ≥ 4 (at least 2 for each nostril) at screening, as determined by the central reader
• Mean NCS ≥ 2 in the 2 weeks prior to Visit 2
• Ongoing documented NP symptoms for > 8 weeks prior to screening such as rhinorrhoea, reduction or loss of smell and/or poor quality/loss of sleep
• SNOT-22 total score ≥ 30 as assessed at screening. Note: approximately 50 participants with a NPS = 4 at screening will receive treatment with tezepelumab.
• Any standard of care for treatment of CRSwNP, which must include treatment with intranasal corticosteroids, provided the participant is stable on that treatment for at least 30 days prior to Visit 1. Investigators should also assure that participants are compliant and on a stable dose of the background INCS during study period.
• Either 1) documented treatment of NP exacerbation with SCS for at least 3 consecutive days or one IM depo-injectable dose (or contraindications/intolerance to) within the past 12 months prior to Visit 1 but not within the last 3 months prior to Visit 1 OR 2) any history of NP surgery (or contraindications/intolerance to)
• Body weight of ≥ 40 kg at Visit 1
• Female participants:
• Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women of non childbearing potential are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal.
• Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned start date of the first IMP administration without an alternative medical cause.

The following age-specific requirements apply:

• Women < 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and FSH levels in the postmenopausal range.
• Women ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
• WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:
• Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
• Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
• Intrauterine device
• Intrauterine hormone-releasing system
• Bilateral tubal occlusion
• Vasectomised partner (vasectomised partner is a highly effective birth control method provided that the partner is the sole sexual partner of the WOCBP participant and that the vasectomised partner has received medical assessment of the surgical success)
• Sexual abstinence: it is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
• Cessation of contraception after this point should be discussed with a responsible physician.
• Provision of signed and dated written ICF as described in Appendix A 3 prior to any mandatory study-specific procedures, sampling, and analyses.
• Participant who is capable of giving signed informed consent as described in Appendix A 3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion Criteria:

• Participants with documented allergic fungal rhinosinusitis and/or central compartment atopic disease.
• Any clinically important pulmonary disease other than asthma (eg, active lung infection, bronchiectasis, pulmonary fibrosis, cystic fibrosis, primary ciliary dyskinesia, allergic bronchopulmonary mycosis, hypereosinophilic syndromes, etc) that could confound interpretation of clinical CRSwNP endpoints results.

• Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

  • Affect the safety of the participant throughout the study
  • Influence the findings of the study or the interpretation
  • Impede the participant's ability to complete the entire duration of study.
• Sinus surgery within 6 months of screening visit OR any sinus surgery in the past which changed the lateral wall of the nose making NPS evaluation impossible.
• Participants with conditions or concomitant disease that makes them non-evaluable for the primary CRSwNP endpoints such as:
• Antrochoanal polyps
• Nasal septal deviation that occludes at least one nostril
• Acute sinusitis, nasal infection, asthma exacerbation or upper respiratory infection at screening or in the two weeks before screening, or Churg-Strauss syndrome (also known as eosinophilic granulomatosis with polyangiitis), Young's syndrome or Kartagener's syndrome

• History of cancer:

  1. Participants who have had basal cell carcinoma, localised squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1.
  2. Participants who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1.
• Uncontrolled epistaxis within 2 months of Visit 1
• A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
• For participants with comorbid asthma: Current smokers or participants with a smoking history ≥ 10 packs per year and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack per year and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.
• History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
• Tuberculosis requiring treatment within the 12 months prior to Visit 1.
• Major surgery within 8 weeks prior to Visit 1 or planned NP surgery or planned surgical procedures requiring general anaesthesia or inpatient status for more than 1 day during the conduct of the study.
• History of known immunodeficiency disorder including a positive HIV test at Visit 1, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
• Infection requiring systemic antibiotics within 14 days prior to Visit 1. Note: Participants with respiratory infections requiring antibiotics within 14 days prior to Visit 1 may extend their screening period to allow recovery and return no sooner than 14 days after completion of therapy.
• Evidence of COVID-19 within 4 weeks prior to screening or ongoing clinically significant COVID-19 sequelae (eg, participants who have long-term post-COVID-19 anosmia).
• Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1.
• Treatment with systemic immunosuppressive/immunomodulating drugs (eg, methotrexate, cyclosporine, etc.), except for SCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.
• Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tezepelumab; Tezepelumab: Tezepelumab single dose subcutaneously injection.	Combination product: Tezepelumab; IMP. Subcutaneous injection. Unit dose strengths 210 mg.; Other Names: TEZSPIRE®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in nasal congestion	Changes from baseline in participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) as part of the nasal polyposis symptom diary (NPSD) following initiation of tezepelumab treatment.	Week 24
Change from baseline in sino-nasal symptoms	changes from baseline in participant reported sino nasal symptoms as evaluated by sino nasal outcome test, 22 item (SNOT 22) total score following initiation of tezepelumab treatment.	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of NCS responders	Proportion of NCS responders (minimal clinically important difference [MCID] from baseline = 1.0) at each collected timepoint.	End of treatment - Week 24
Time to first response for NCS	Description of time to first response for NCS by analysing data at all collected timepoints.	End of Treatment-week 24
Change from baseline in NCS	Change from baseline in NCS at each collected timepoint.	Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24).
Proportion of SNOT-22 responders	Proportion of SNOT-22 responders (MCID from baseline = -8.9) at each collected timepoint.	Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
Time to first response for SNOT-22	Description of time to first response for SNOT-22 by analysing data at all collected timepoints.	Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
Change from baseline in SNOT-22	Change from baseline in SNOT-22 at each collected timepoint.	Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
Change from baseline visit in nasal blockage (NB)	Change from baseline visit in NB measured by PNIF	Weeks 0, 4, 12, and 24.
Change from baseline visit in NB	Change from baseline visit in NB measured by VAS-NB	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
Proportion of PNIF responders	Proportion of PNIF responders (MCID from baseline =20 L/min).	Weeks 0, 4, 12, and 24.
Proportion of VAS-NB responders	Proportion of VAS-NB responders (MCID from baseline = -3.0) (in participants with VAS-NB ≥ 7 at baseline).	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
Time to first response for PNIF	Description of time to first response for PNIF by analysing data at all collected timepoints.	Weeks 0, 4, 12, and 24
First response for VAS NB	Description of time to first response for VAS NB by analysing data at all collected timepoints (in participants with VAS-NB ≥ 7 at baseline).	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
Change from baseline in loss of smell score evaluated by UPSIT or Sniffin Sticks	Change from baseline in loss of smell score evaluated by UPSIT or Sniffin Sticks	Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
Change from baseline in loss of smell score evaluated by VAS-Taste	Change from baseline in loss of smell score evaluated by VAS-Taste	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Change from baseline in loss of smell score evaluated by VAS-Smell	Change from baseline in loss of smell score evaluated by VAS-Smell	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Proportion of UPSIT responders	Proportion of UPSIT responders (MCID from baseline = 4)	Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24.
Proportion of Sniffin sticks responders	Proportion of Sniffin sticks responders (MCID from baseline = 6)	Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
Proportion of VAS-Smell responders	Proportion of VAS-Smell responders (MCID from baseline = -3.0) (in participants with VAS-Smell ≥ 7 at baseline)	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Proportion of participants with a reduction in VAS-Taste score from baseline	Proportion of participants with a reduction in VAS-Taste score from baseline (in participants with VAS-Taste ≥ 7 at baseline)	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Time to first response for UPSIT/Sniffin sticks	Time to first response for UPSIT/Sniffin sticks by analysing data at all collected timepoints.	Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
Time to first response for VAS Smell	Time to first response for VAS Smell by analysing data at all collected timepoints (in participants with VAS-Smell ≥ 7 at baseline).	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Time to first improvement in VAS-Taste	Time to first improvement in VAS-Taste by analysing data at all collected timepoints (in participants with VAS-Taste ≥ 7 at baseline).	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Change from baseline in sleep as evaluated by PSQI total score	Change from baseline in sleep as evaluated by PSQI total score	Weeks 0, 12, and 24.
Change from baseline in sleep as evaluated by SNOT-22 Sleep domain score	Change from baseline in sleep as evaluated by SNOT-22 Sleep domain score	Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
Change from baseline in sleep as evaluated by VAS-Sleep	Change from baseline in sleep as evaluated by VAS-Sleep	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Proportion of PSQI responders	Proportion of PSQI responders (MCID from baseline = - 4.4)	Weeks 0, 12, and 24
Proportion of SNOT-22 Sleep domain responders	Proportion of SNOT-22 Sleep domain responders (MCID from baseline = -2.9)	Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
Proportion of participants with any improvement in VAS Sleep from baseline	Proportion of participants with any improvement in VAS Sleep from baseline (in participants with VAS-Sleep ≥ 7 at baseline)	Daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Time to first response for PSQI	Time to first response for PSQI by analysing data at all collected timepoints.	Weeks 0, 12, and 24.
Time to first response for SNOT-22 Sleep domain	Time to first response for SNOT-22 Sleep domain by analysing data at all collected timepoints.	Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24.
Time to first improvement for VAS-Sleep	Time to first improvement for VAS-Sleep by analysing data at all collected timepoints (in participants with VAS-Sleep ≥ 7 at baseline).	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Change from baseline in total NPS	Change from baseline in total NPS evaluated by nasal endoscopy.	Screening, Weeks 2 and 24
Proportion of NPS responders	Proportion of NPS responders (MCID from baseline = 1.0) at Weeks 2 and 24.	Screening, Weeks 2 and 24
Change from baseline in NPQ score	Change from baseline in NPQ score	Weeks 0, 8, 12, and 24.
Proportion of NPQ responders	Proportion of NPQ responders (MCID from baseline = 7.0)	Weeks 0, 8, 12, and 24
Time to first response for NPQ	Time to first response for NPQ by analysing data collected at each specified timepoint.	Weeks 0, 8, 12, and 24.
Change from baseline in TSS	Change from baseline in TSS	daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
Proportion of TSS responders	Proportion of TSS responders (MCID from baseline = 4.0)	daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
Time to first response for TSS	Time to first response for TSS by analysing data at all collected timepoints.	daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
Change from baseline in NP severity	Change from baseline in NP severity as measured by VAS Overall symptoms	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Proportion of VAS Overall symptom responders	Proportion of VAS Overall symptom responders (MCID from baseline = 2.5)	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Time to first response for VAS-Overall symptom	Time to first response for VAS-Overall symptom by analysing data at all collected timepoints	daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Proportion of participants who respond as 'well controlled' or 'completely controlled' NP symptoms to the NP control question	Proportion of participants who respond as 'well controlled' or 'completely controlled' NP symptoms to the NP control question	Weeks 0, 4, 8, 12, 20, and 24.
Time to first response for NP control	Time to first response for NP control by analysing data at all collected timepoints.	Weeks 0, 4, 8, 12, 20, and 24.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Endoscopy findings will be used to describe histological changes and describe CRSwNP visualization	Endoscopy findings will be used to describe histological changes and describe CRSwNP visualization from baseline to Week 24.	Screening, Weeks 2 and 24
Change from baseline in blood eosinophil count (BEC), total serum IgE, specific IgE (including fungi/moulds [eg, Alternaria]), S. aureus enterotoxin IgE, and Fractional exhaled nitric oxide (FeNO; for asthma participants only)	Change from baseline in blood eosinophil count (BEC), total serum IgE, specific IgE (including fungi/moulds [eg, Alternaria]), S. aureus enterotoxin IgE, and Fractional exhaled nitric oxide (FeNO; for asthma participants only)	Screening (for BEC and FeNO), Week 0 (for IgE and S. aureus enterotoxin IgE), Weeks 12 and 24
Change from baseline in WPAI-CRSwNP	Change from baseline in WPAI-CRSwNP	Week 0 and Week 24
Proportion and annualised rate of primary care visits (all rates for CRSwNP-related and asthma-related).	Proportion and annualised rate of primary care visits (all rates for CRSwNP-related and asthma-related).	24 weeks pre-and post index (index = 1st tezepelumab dosing).
Change in incident rate of nasal infection comparing the post-index period versus the pre-index period	Change in incident rate of nasal infection comparing the post-index period versus the pre-index period (index = 1st tezepelumab dosing).	24 weeks pre- and post-index. (index = 1st tezepelumab dosing)
Change in proportion of participants with CRSwNP-related SCS use during the post-index period (24 weeks following tezepelumab first dose) versus the pre-treatment period (24 weeks prior to tezepelumab first dose)	Change in proportion of participants with CRSwNP-related SCS use during the post-index period (24 weeks following tezepelumab first dose) versus the pre-treatment period (24 weeks prior to tezepelumab first dose)	24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
Change in average SCS daily dose during the post-index period versus dose at/closest to the index	Change in average SCS daily dose during the post-index period (24 weeks following tezepelumab first dose) versus dose at/closest to the index	24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
Proportion of participants with the decision for CRSwNP surgery during the 24 weeks pre- and post-index and change in NP surgery proportion following tezepelumab initiation.	Proportion of participants with the decision for CRSwNP surgery during the 24 weeks pre- and post-index and change in NP surgery proportion following tezepelumab initiation.	24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
Proportion of patients with CRSwNP exacerbation	Proportion of patients with CRSwNP exacerbation	24-weeks pre- and post-index (index = 1st tezepelumab dosing).
Change since baseline in Asthma Control Questionnaire 6 (ACQ-6) score	Change since baseline in Asthma Control Questionnaire 6 (ACQ-6) score	Weeks 0 and 24.
ACQ-6 responder: proportion of participants with change since baseline in ACQ-6 of 0.5 or above	ACQ-6 responder: proportion of participants with change since baseline in ACQ-6 of 0.5 or above	Weeks 0 and 24
Annualised asthma exacerbation rate	Annualised asthma exacerbation rate	24 weeks pre-and post-index (index = 1st tezepelumab dosing).
Change from baseline in Annualised asthma exacerbation rate	Change from baseline in Annualised asthma exacerbation rate	24 weeks pre-and post-index (index = 1st tezepelumab dosing).
Lung function (Forced expiratory volume in 1 second [FEV1]) (if available at site)	Lung function (Forced expiratory volume in 1 second [FEV1]) (if available at site)	Weeks 0, 12 (lung function only) and 24.
Asthma-related SCS use (yes/no)	Asthma-related SCS use (yes/no)	24 weeks pre-and post-index (index = 1st tezepelumab dosing).
Proportion and annualised rate of urgent care (all rates for CRSwNP-related and asthma-related).	Proportion and annualised rate of urgent care (all rates for CRSwNP-related and asthma-related).	24 weeks pre-and post index (index=1st tezepelumab dosing)
Proportion and annualised rate of unplanned surgery (all rates for CRSwNP-related and asthma-related).	Proportion and annualised rate of unplanned surgery (all rates for CRSwNP-related and asthma-related).	24 weeks pre and post index (index=ist tezepelumab dosing)
Proportion and annualised rate of unplanned out participant visits (all rates for CRSwNP-related and asthma-related).	Proportion and annualised rate of unplanned out participant visits (all rates for CRSwNP-related and asthma-related).	24 weeks pre- and post index (index=1st tezepelumab dosing)
Proportion and annualised rate of emergency room visits (all rates for CRSwNP-related and asthma-related).	Proportion and annualised rate of emergency room visits (all rates for CRSwNP-related and asthma-related).	24 weeks pre-and post index (index=1st tezepelumab dosing)
Proportion and annualised rate of hospitalisations (all rates for CRSwNP-related and asthma-related).	Proportion and annualised rate of hospitalisations (all rates for CRSwNP-related and asthma-related).	24 weeks pre-and post index(index=1st tezepelumab dosing)
Asthma related SCS use as part of an exacerbation	Asthma related SCS use as part of an exacerbation	24 weeks pre-and post index(index=1st tezepelumab dosing)
Asthma related SCS duration of use	Asthma related SCS duration of use	24 weeks pre-and post index(index=1st tezepelumab dosing)
Asthma related SCS daily dose	Asthma related SCS daily dose	24 weeks pre-and post index(index=1st tezepelumab dosing)

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Fortrea
• Investigators: Principal Investigator: Tanya M Laidlaw, MD, Director of Translational Research in Allergy and Director of the Aspirin-Exacerbated Respiratory Disease (AERD) Centre at the Brigham and Women's Hospital.; Principal Investigator: Enrico Heffler, MD, PhD, Associate Professor of Internal Medicine and Consultant at the Personalized Medicine, Asthma and Allergy Unit at IRCCS Humanitas Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 3, 2024
• Primary Completion (Estimated): January 13, 2027
• Study Completion (Estimated): January 13, 2027

Study Registration Dates

• First Submitted: November 7, 2024
• First Submitted That Met QC Criteria: November 22, 2024
• First Posted (Actual): November 27, 2024

Study Record Updates

• Last Update Posted (Actual): April 20, 2026
• Last Update Submitted That Met QC Criteria: April 17, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Rhinosinusitis; Chronic rhinosinusitis
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Nose Diseases; Otorhinolaryngologic Diseases; Rhinitis; Sinusitis; Paranasal Sinus Diseases; Rhinosinusitis; tezepelumab
• Other Study ID Numbers: D5242C00002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes